Search

Your search keyword '"Peter Tan"' showing total 215 results

Search Constraints

Start Over You searched for: Author "Peter Tan" Remove constraint Author: "Peter Tan"
215 results on '"Peter Tan"'

Search Results

51. Ideal Laws, Counterfactual Preservation, and the Analyses of Lawhood

52. WHY INNOVATE IN MARKETING? A CASE OF POSH NAIL SPA

54. End-of-Life Care Among Patients With Kidney Failure on Maintenance Dialysis: A Retrospective Population-Based Study

55. Barriers to Discharge of Hip Fracture Patients From An Academic Hospital: A Retrospective Data Analysis

56. What are the views of Quebec and Ontario citizens on the tiebreaker criteria for prioritizing access to adult critical care in the extreme context of a COVID-19 pandemic?

57. Study protocol for the development and validation of a clinical prediction tool to estimate the risk of 1-year mortality among hospitalized patients with dementia

58. Proteomic analysis of decellularized mice liver and kidney extracellular matrices

59. Involvement of Palliative Care in Malignant Pleural Mesothelioma Patients and Associations with Survival and End-of-Life Outcomes

60. Inconsistent idealizations and inferentialism about scientific representation

61. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study

62. Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation

63. COVID-19 vaccine uptake among Ontario physicians: a descriptive population-based retrospective cohort study

64. Depletion of donor dendritic cells ameliorates immunogenicity of both skin and hind limb transplants

65. The association between physical availability of cannabis retail outlets and frequent cannabis use and related health harms: a systematic review

66. Prevalence and patterns of multimorbidity among linguistic groups of patients receiving home care in Ontario: a retrospective cohort study

67. Interventions and Counternomic Reasoning

68. Diagnosis and treatment ofMYH9-RD in an Australasian cohort with thrombocytopenia

69. Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia

70. Post-transitional adaptation of the left heart in uncomplicated, very preterm infants

71. Identifying predictors of cognitive decline in long-term care: a scoping review

72. Intensity of end-of-life care among children with life-threatening conditions: a national population-based observational study

73. Association of virtual end-of-life care with healthcare outcomes before and during the COVID-19 pandemic: A population-based study.

74. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study

75. Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)

76. PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG-120) IN COMBINATION WITH AZACITIDINE FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

78. Cardiac Function After the Immediate Transitional Period in Very Preterm Infants Using Speckle Tracking Analysis

79. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia

80. Systematic review of validated case definitions to identify hypertensive disorders of pregnancy in administrative healthcare databases

81. Stroke Subtype Among Individuals With Chronic Kidney Disease

82. Diagnosis and treatment of

84. Improving social justice in observational studies: protocol for the development of a global and Indigenous STROBE-equity reporting guideline

85. A population‐based study of factors associated with systemic treatment in advanced prostate cancer decedents

86. Describing settings of care in the last 100 days of life for cancer decedents: a population‐based descriptive study

87. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome

88. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with azacitidine (AZA) for newly diagnosed acute myeloid leukemia (ND AML)

89. Initial treatment is associated with improved survival and end-of-life outcomes for patients with pancreatic cancer: a cohort study

90. New or existing, does it matter?

91. Caring for older men and women: whose caregivers are more distressed? A population-based retrospective cohort study

92. Exploring Primary Care Physicians’ Experiences of Language and Cultural Discordant Care for Linguistic Minority Patients at the End-of-Life: A Study Protocol

93. Comorbidities, symptoms and end-of-life medication use in hospitalised decedents before and during the COVID-19 pandemic: a retrospective regional cohort study in Ottawa, Canada

94. Higher Education Institutions and ASEAN: Current Trends and Implications for Future Innovation and Change

95. Mapping Cropping Practices Using MODIS Time Series: Harnessing the Data Explosion

96. An Evaluation of the Use of Atmospheric and BRDF Correction to Standardize Landsat Data

97. Development and Validation of a Predictive Risk Algorithm for Bleeding in Individuals on Long-term Hemodialysis: An International Prospective Cohort Study (BLEED-HD)

98. Characteristics and Outcomes of ICU Patients Without COVID-19 Infection—Pandemic Versus Nonpandemic Times: A Population-Based Cohort Study

99. Physician benzodiazepine self-use prior to and during the COVID-19 pandemic in Ontario, Canada: a population-level cohort study

100. Mental health and addiction health service use by physicians compared to non-physicians before and during the COVID-19 pandemic: A population-based cohort study in Ontario, Canada.

Catalog

Books, media, physical & digital resources